The restrictions are:
• Induction therapy is started when either the cytogenetic test confirms that the disease has favourable, intermediate or unknown cytogenetics (that is, because the test was unsuccessful) or when their cytogenetic test results are not yet available and
• Consolidation therapy is started when their cytogenetic test confirms that the disease has favourable, intermediate or unknown cytogenetics (because the test was unsuccessful) and
• The company provides gemtuzumab ozogamicin according to the commercial arrangement.